P2Y receptors as regulators of lung endothelial barrier integrity

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Endothelial cells (ECs), forming a semi-permeable barrier between the interior space of blood vessels and underlying tissues, control such diverse processes as vascular tone, homeostasis, adhesion of platelets, and leukocytes to the vascular wall and permeability of vascular wall for cells and fluids. Mechanisms which govern the highly clinically relevant process of increased EC permeability are under intense investigation. It is well known that loss of this barrier (permeability increase) results in tissue inflammation, the hall mark of inflammatory diseases such as acute lung injury and its severe form, acute respiratory distress syndrome. Little is known about processes which determine the endothelial barrier enhancement or protection against permeability increase. It is now well accepted that extracellular purines and pyrimidines are promising and physiologically relevant barrier-protective agents and their effects are mediated by interaction with cell surface P2Y receptors which belong to the superfamily of G-protein-coupled receptors. The therapeutic potential of P2Y receptors is rapidly expanding field in pharmacology and some selective agonists became recently available. Here, we present an overview of recently identified P2Y receptor agonists that enhance the pulmonary endothelial barrier and inhibit and/or reverse endothelial barrier disruption.

Original languageEnglish (US)
Pages (from-to)14-22
Number of pages9
JournalJournal of Cardiovascular Disease Research
Volume2
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Blood Vessels
Permeability
Lung
Endothelial Cells
Protective Agents
Pyrimidines
Purines
Acute Lung Injury
Adult Respiratory Distress Syndrome
Capillary Permeability
Cell Surface Receptors
G-Protein-Coupled Receptors
Cell Wall
Leukocytes
Homeostasis
Blood Platelets
Pharmacology
Inflammation
Therapeutics

Keywords

  • EPAC
  • MLC-phosphatase
  • VE-cadherin
  • lipopolysaccharide
  • microvascular endothelium
  • permeability

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

P2Y receptors as regulators of lung endothelial barrier integrity. / Zemskov, Evgeny Alexandrovich; Lucas, Rudolf; Verin, Alexander Dmitriyevich; Siddaramappa, Umapathy N.

In: Journal of Cardiovascular Disease Research, Vol. 2, No. 1, 01.01.2011, p. 14-22.

Research output: Contribution to journalArticle

@article{51c88f62636d46b3bbc962c0de2df898,
title = "P2Y receptors as regulators of lung endothelial barrier integrity",
abstract = "Endothelial cells (ECs), forming a semi-permeable barrier between the interior space of blood vessels and underlying tissues, control such diverse processes as vascular tone, homeostasis, adhesion of platelets, and leukocytes to the vascular wall and permeability of vascular wall for cells and fluids. Mechanisms which govern the highly clinically relevant process of increased EC permeability are under intense investigation. It is well known that loss of this barrier (permeability increase) results in tissue inflammation, the hall mark of inflammatory diseases such as acute lung injury and its severe form, acute respiratory distress syndrome. Little is known about processes which determine the endothelial barrier enhancement or protection against permeability increase. It is now well accepted that extracellular purines and pyrimidines are promising and physiologically relevant barrier-protective agents and their effects are mediated by interaction with cell surface P2Y receptors which belong to the superfamily of G-protein-coupled receptors. The therapeutic potential of P2Y receptors is rapidly expanding field in pharmacology and some selective agonists became recently available. Here, we present an overview of recently identified P2Y receptor agonists that enhance the pulmonary endothelial barrier and inhibit and/or reverse endothelial barrier disruption.",
keywords = "EPAC, MLC-phosphatase, VE-cadherin, lipopolysaccharide, microvascular endothelium, permeability",
author = "Zemskov, {Evgeny Alexandrovich} and Rudolf Lucas and Verin, {Alexander Dmitriyevich} and Siddaramappa, {Umapathy N}",
year = "2011",
month = "1",
day = "1",
doi = "10.4103/0975-3583.78582",
language = "English (US)",
volume = "2",
pages = "14--22",
journal = "Journal of Cardiovascular Disease Research",
issn = "0975-3583",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "1",

}

TY - JOUR

T1 - P2Y receptors as regulators of lung endothelial barrier integrity

AU - Zemskov, Evgeny Alexandrovich

AU - Lucas, Rudolf

AU - Verin, Alexander Dmitriyevich

AU - Siddaramappa, Umapathy N

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Endothelial cells (ECs), forming a semi-permeable barrier between the interior space of blood vessels and underlying tissues, control such diverse processes as vascular tone, homeostasis, adhesion of platelets, and leukocytes to the vascular wall and permeability of vascular wall for cells and fluids. Mechanisms which govern the highly clinically relevant process of increased EC permeability are under intense investigation. It is well known that loss of this barrier (permeability increase) results in tissue inflammation, the hall mark of inflammatory diseases such as acute lung injury and its severe form, acute respiratory distress syndrome. Little is known about processes which determine the endothelial barrier enhancement or protection against permeability increase. It is now well accepted that extracellular purines and pyrimidines are promising and physiologically relevant barrier-protective agents and their effects are mediated by interaction with cell surface P2Y receptors which belong to the superfamily of G-protein-coupled receptors. The therapeutic potential of P2Y receptors is rapidly expanding field in pharmacology and some selective agonists became recently available. Here, we present an overview of recently identified P2Y receptor agonists that enhance the pulmonary endothelial barrier and inhibit and/or reverse endothelial barrier disruption.

AB - Endothelial cells (ECs), forming a semi-permeable barrier between the interior space of blood vessels and underlying tissues, control such diverse processes as vascular tone, homeostasis, adhesion of platelets, and leukocytes to the vascular wall and permeability of vascular wall for cells and fluids. Mechanisms which govern the highly clinically relevant process of increased EC permeability are under intense investigation. It is well known that loss of this barrier (permeability increase) results in tissue inflammation, the hall mark of inflammatory diseases such as acute lung injury and its severe form, acute respiratory distress syndrome. Little is known about processes which determine the endothelial barrier enhancement or protection against permeability increase. It is now well accepted that extracellular purines and pyrimidines are promising and physiologically relevant barrier-protective agents and their effects are mediated by interaction with cell surface P2Y receptors which belong to the superfamily of G-protein-coupled receptors. The therapeutic potential of P2Y receptors is rapidly expanding field in pharmacology and some selective agonists became recently available. Here, we present an overview of recently identified P2Y receptor agonists that enhance the pulmonary endothelial barrier and inhibit and/or reverse endothelial barrier disruption.

KW - EPAC

KW - MLC-phosphatase

KW - VE-cadherin

KW - lipopolysaccharide

KW - microvascular endothelium

KW - permeability

UR - http://www.scopus.com/inward/record.url?scp=79955079450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955079450&partnerID=8YFLogxK

U2 - 10.4103/0975-3583.78582

DO - 10.4103/0975-3583.78582

M3 - Article

C2 - 21716747

AN - SCOPUS:79955079450

VL - 2

SP - 14

EP - 22

JO - Journal of Cardiovascular Disease Research

JF - Journal of Cardiovascular Disease Research

SN - 0975-3583

IS - 1

ER -